The MARIPOSA trial is a phase III study currently underway that is evaluating the efficacy of amivantamab with lazertinib compared to osimertinib, a well-established third generation TKI in the treatment of EGFR-mutant (exon 19 deletions or exon 21 L858R substitution) NSCLC (NCT04487080), (Table 2) [45]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.